I'm pretty sure that Trump thing came up as a question at the Q1 call. Look up the transcript. This rollercoaster is really frustrating, to say the least. There is no doubt in my mind that Cytosorb will be successful, but the company seeming to not care about the share price is maddening. The lower share price means higher dilution when a capital raise comes... I said it many times before and I still think the company kept the price under $8 deliberately by using the ATM. We are still up 50% from that level at least.
The thing that bothers me the most is the manufacturing capacity. Correct me if I am wrong, but did I hear that 80M capacity should cover them 3-5 years? I hope I heard that wrong, because that works out to 20% Q over Q growth, which would be great for most companies, but if you are seriously expecting an FDA approval in 2 years, that makes no sense.
Come on guys, conservative optimism is one thing, but but if you really believe you have a paradigm shifting medical treatment, which I think they do, the WORLD needs to know.
News 
Market Data 
Discover 
